Trade bluebird bio, Inc. - BLUE CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.07 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023512% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.00129% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 6.94 |
| Open | 4.58 |
| 1-Year Change | 328.04% |
| Day's Range | 4.02 - 4.58 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Feb 21, 2025 | 4.04 | -0.82 | -16.87% | 4.86 | 5.64 | 3.99 |
| Feb 20, 2025 | 6.94 | -0.10 | -1.42% | 7.04 | 7.14 | 6.85 |
| Feb 19, 2025 | 7.12 | 0.15 | 2.15% | 6.97 | 7.23 | 6.55 |
| Feb 18, 2025 | 7.02 | -0.21 | -2.90% | 7.23 | 7.49 | 6.89 |
| Feb 14, 2025 | 7.19 | 0.14 | 1.99% | 7.05 | 7.47 | 6.97 |
| Feb 13, 2025 | 7.16 | 0.94 | 15.11% | 6.22 | 7.37 | 6.18 |
| Feb 12, 2025 | 6.37 | 0.46 | 7.78% | 5.91 | 6.38 | 5.85 |
| Feb 11, 2025 | 5.98 | -0.23 | -3.70% | 6.21 | 6.23 | 5.88 |
| Feb 10, 2025 | 6.15 | -0.04 | -0.65% | 6.19 | 6.22 | 6.02 |
| Feb 7, 2025 | 6.18 | -0.50 | -7.49% | 6.68 | 6.71 | 6.05 |
| Feb 6, 2025 | 6.65 | -0.19 | -2.78% | 6.84 | 7.00 | 6.51 |
| Feb 5, 2025 | 6.92 | 0.03 | 0.44% | 6.89 | 7.20 | 6.80 |
| Feb 4, 2025 | 6.88 | -0.06 | -0.86% | 6.94 | 7.23 | 6.76 |
| Feb 3, 2025 | 6.98 | -0.41 | -5.55% | 7.39 | 7.50 | 6.90 |
| Jan 31, 2025 | 7.66 | -0.24 | -3.04% | 7.90 | 8.17 | 7.63 |
| Jan 30, 2025 | 7.83 | 0.24 | 3.16% | 7.59 | 8.09 | 7.42 |
| Jan 29, 2025 | 7.45 | -0.22 | -2.87% | 7.67 | 7.80 | 7.18 |
| Jan 28, 2025 | 7.63 | 0.08 | 1.06% | 7.55 | 7.80 | 7.31 |
| Jan 27, 2025 | 7.49 | -0.19 | -2.47% | 7.68 | 8.19 | 7.36 |
| Jan 24, 2025 | 7.69 | -0.01 | -0.13% | 7.70 | 8.15 | 7.64 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Bluebird Company profile
bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease. The company's lead product candidates in oncology include bb2121 and bb21217, which are anti- B-cell maturation antigens in Phase I clinical trials for the treatment of relapsed/refractory multiple myeloma. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology. It also has collaborations with Medigene AG for the research and development of T cell receptor product candidates directed against antigens for the treatment of cancer indications; and TC BioPharm Limited to research and develop gamma delta chimeric antigen receptor modified T cell product candidates for cancer immunotherapy, as well as a partnership agreement with Celgene European Investment Company LLC. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.| Industry: | Bio Therapeutic Drugs |
455 Grand Union Boulevard
SOMERVILLE
MASSACHUSETTS 02145
US
News
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025
Ripple XRP price prediction: Third-party price target
Discover the ripple (XRP) price predictions for 2025 and beyond, with analyst price targets and CFDs trading strategies on Capital.com
15:29, 6 February 2025
Apple (AAPL) stock price forecast: third-party price target
We looked at the forecasts for Apple stock in 10 years to see where the price would likely be at that point and the challenges the company could face. Read more.
11:22, 6 February 2025
FARTCOIN price prediction: Third-party price target
Read our FARTCOIN price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:18, 29 January 2025
MELANIA coin ($MELANIA) price prediction: Third party price target
Read our MELANIA crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts.
11:33, 22 January 2025
TRUMP coin ($TRUMP) price prediction: third-party price target
Read our TRUMP crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:52, 22 January 2025
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025People also watch
Still looking for a broker you can trust?
Join the 690,000+ traders worldwide that chose to trade with Capital.com